What is the present valuation and projected CAGR of the guillain-barre syndrome market?
The guillain-barre syndrome market size has grown strongly in recent years. It will grow from $0.60 billion in 2024 to $0.64 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to rising demand for GBS treatments, rising viral infections, growing global vaccination campaigns, rising understanding of autoimmune mechanisms, and increasing awareness and diagnosis.
The guillain-barre syndrome market size is expected to see strong growth in the next few years. It will grow to $0.79 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to increasing prevalence of guillain-barre syndrome, growing impact of climate change, increasing use of immunotherapies and drugs, increasing diagnostic capabilities, and rising prevalence of multifocal motor neuropathy. Major trends in the forecast period include enhanced diagnostic techniques, development of immunoglobulin therapies, improved plasmapheresis methods, exploration of gene therapy, increased focus on early intervention, novel biomarkers for prognosis, and expanded clinical trials for innovative treatments.
Get Your Free Sample of The Global Guillain-Barre Syndrome Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21198&type=smp
What key drivers have fueled the guillain-barre syndrome market’s development over the years?
The increasing risk of immunological diseases is expected to propel the growth of the guillain-barre syndrome market going forward. Immunological diseases are conditions where the immune system is overactive, underactive, or misdirected, leading to disorders such as autoimmune diseases, allergies, or immunodeficiencies. Immunological diseases are increasing due to factors such as environmental changes, lifestyle, better diagnosis, and genetic predisposition. Immunological diseases can cause guillain-barré syndrome by triggering an autoimmune response in which the body’s immune system mistakenly attacks the peripheral nerves, leading to inflammation and nerve damage. For instance, in July 2024, according to a report published by the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based government organization, by the end of 2022, approximately 39.5 million people worldwide were living with HIV, with 1.3 million new infections and 630,000 AIDS-related deaths reported that year. In 2023, the number of people living with HIV globally rose to around 39.9 million. Therefore, the increasing risk of immunological diseases is driving the guillain-barre syndrome market.
What is the segmentation for the guillain-barre syndrome market?
The guillain-barre syndrome market covered in this report is segmented –
1) By Type: Acute Inflammatory Demyelinating Polyneuropathy (AIDP), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN), Other Types
2) By Therapeutics: Intravenous Immunoglobulin (IVIG), Plasma Exchange, Other Therapeutics
3) By Route Of Administration: Parenteral, Oral
4) By End User: Hospitals, Clinics, Diagnostic Centers, Other End Users
Subsegments:
1) By Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Classical AIDP, AIDP with Autonomic Involvement
2) By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Progressive CIDP, Relapsing-Remitting CIDP, Multifocal CIDP
3) By Miller Fisher Syndrome (MFS): Classical MFS, MFS With Ataxia, MFS With Ophthalmoplegia
4) By Acute Motor Axonal Neuropathy (AMAN): Classical AMAN, AMAN with Respiratory Involvement
5) By Other Types: Acute Sensory Ganglionopathy, Variants With Cranial Nerve Involvement, Bickerstaff Brainstem Encephalitis
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-global-market-report
Who are the most influential companies in the guillain-barre syndrome market?
Major companies operating in the guillain-barre syndrome market are Pfizer Inc., Roche AG, Thermo Fisher Scientific Inc., AstraZeneca PLC, GSK plc, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., Baxter International Inc., Biogen Inc., Horizon Therapeutics, Octapharma AG, Kedrion S.p.A., Annexon Inc., Immunovant Inc., CSL Behring LLC, Hansa Biopharma AB, NeuLine Health Inc., Ridge Diagnostics Inc., Deymed Diagnostic LLC, VYVGART Hytrulo.
What are the top industry trends projected to impact the guillain-barre syndrome market?
Major companies operating in the guillain-barre syndrome market are prioritizing innovative drug development, such as monoclonal antibodies, to enhance treatment efficacy, address unmet clinical needs, and expand their market presence. Monoclonal antibodies are laboratory-engineered proteins designed to target specific antigens, helping modulate immune responses and improve therapeutic outcomes. For instance, in October 2023, Annexon Inc., a US-based biopharmaceutical company, received orphan drug designation by the European Medicines Agency (EMA) for its drug ANX005 for the treatment of guillain-barre syndrome (GBS). It is a monoclonal antibody targeting C1q, demonstrating early muscle strength improvements and reduced need for ventilation compared to IVIg, marking it as a significant therapeutic advancement.
What are the major regional insights for the guillain-barre syndrome market, and which region holds the top position?
North America was the largest region in the guillain-barre syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Guillain-Barre Syndrome Market Report 2025 Offer?
The guillain-barre syndrome market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Guillain-barre syndrome is a rare neurological disorder in which the body’s immune system mistakenly attacks the peripheral nervous system. This can lead to muscle weakness, numbness, tingling, and, in severe cases, paralysis. The exact cause is unknown, but it is triggered by infections, such as respiratory or gastrointestinal infections, and sometimes by vaccinations or surgery.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21198
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
